Find a Study

STUDY SEARCH RESULTS

Notify Me When Search is Updated

19 studies found for your search request: Mk2870

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination with Pembrolizumab (MK-3475) as...
Condition: Cervical cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT07216703
Status: Recruiting
Has Enrolling Locations in US or Canada

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients with Bladder Cancer (MK-2870-027)
Condition: Non-Muscle Invasive Bladder Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06637423
Status: Recruiting
Has Enrolling Locations in US or Canada

A clinical study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) in people with breast cancer (MK-2870...
Condition: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT06966700
Status: Recruiting
Has Enrolling Locations in US or Canada

A clinical trial of sac-TMT in people with non-HRD positive advanced ovarian cancer (MK-2870-021)
Condition: Ovarian Neoplasms, Ovarian Cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT07318558
Status: Recruiting
Has Enrolling Locations in US or Canada

A clinical trial of sacituzumab tirumotecan (Sac-TMT, MK-2870) to treat urothelial cancer (MK-2870-0...
Condition: Bladder cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT07419295
Status: Recruiting
Has Enrolling Locations in US or Canada

Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences Privacy Terms of Use Consumer Health Data Privacy Policy Your Privacy Choices Accessibility U.S. Corporate Site